Circadian profiles of blood glucose and plasma free insulin during treatment with Semisynthetic and Biosynthetic human insulin, and comparison with conventional monocomponent preparations
- 1 January 1983
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 25 (6) , 767-771
- https://doi.org/10.1007/bf00542517
Abstract
Sixteen hospitalized insulin requiring diabetics treated with a single daily subcutaneous injection were randomly allocated either to a mixture of porcine Actrapid+Lente MC or a mixture of Regular+NPH—Biosynthetic human insulin (Study 1). In Study 2, 10 patients receiving two daily insulin injections were treated at random with either porcine Actrapid+Monotard, or Actrapid+Monotard—Semisynthetic human insulin or Regular+NPH—Biosynthetic human insulin. Once an optimal insulin regimen was obtained, circadian blood glucose and plasma free insulin profiles (7–9 time points) were determined with the two (Study 1) or three (Study 2) insulin preparations, keeping the doses of insulin constant. In Study 1 no significant difference in blood glucose (BG) or plasma free insulin (FIRI) profiles was observed. The mean daily blood glucose, the mean amplitude of glycaemic excursions (MAGE), the index of blood glucose control (M-value of Schlichtkrull), as well as the post-breakfast increases in blood glucose and mean free IRI, were similar with both types of insulin. In Study 2, BG and FIRI profiles were also similar, except for a significantly lower (p<0.02) BG at 8.30 p.m. with both human insulins. No significant differences were found in free IRI at that time. Mean BG, M index, MAGE and mean FIRI were similar but the postbreakfast increase was significantly smaller with SHI. In conclusion, the pharmacokinetics of animal monocomponent, semisynthetic and biosynthetic human insulin appear similar, but evening BG control was better with both types of human insulins given twice daily.This publication has 16 references indexed in Scilit:
- Human Insulin of Recombinant DNA Origin: Clinical PotentialDiabetes Care, 1982
- Human insulin: study of safety and efficacy in man.BMJ, 1981
- Chemical, Physical, and Biologic Properties of Biosynthetic Human InsulinDiabetes Care, 1981
- HUMAN INSULIN PRODUCED BY RECOMBINANT DNA TECHNOLOGY: SAFETY AND HYPOGLYCÆMIC POTENCY IN HEALTHY MENThe Lancet, 1980
- Dosage of hemoglobin A1c by isoelectrofocusingClinica Chimica Acta; International Journal of Clinical Chemistry, 1978
- Radioimmunological determination of human C-peptide in serumDiabetologia, 1975
- A Simple Method for the Determination of Serum Free Insulin Levels in Insulin-treated PatientsDiabetes, 1973
- Radioimmunoelectrophoresis in the Determination of Insulin Binding to IgG. Methodological StudiesHormone and Metabolic Research, 1973
- Mean Amplitude of Glycemic Excursions, a Measure of Diabetic InstabilityDiabetes, 1970
- The M‐Value, an Index of Blood‐sugar Control in DiabeticsActa Medica Scandinavica, 1965